Glatiramer Acetate Injection, Solution
NDC Package 0832-6085-12
Package Information
Glatiramer Acetate (glatiramer acetate injection) injection is a medication used to treat multiple sclerosis (MS). This formulation utilizes a injection, solution delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 0832-6085 and is authorized under FDA application ANDA214741.
Identification & Billing
- RxCUI: 1111641 - glatiramer acetate 20 MG in 1 ML Prefilled Syringe
- RxCUI: 1111641 - 1 ML glatiramer acetate 20 MG/ML Prefilled Syringe
- RxCUI: 1111641 - glatiramer acetate 20 MG per 1 ML Prefilled Syringe
- RxCUI: 1487361 - glatiramer acetate 40 MG/ML in 1 ML Prefilled Syringe
- RxCUI: 1487361 - 1 ML glatiramer acetate 40 MG/ML Prefilled Syringe
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0832 - Upsher-smith Laboratories, Llc
- 0832-6085 - Glatiramer Acetate
- 0832-6085-12 - 12 SYRINGE, GLASS in 1 CARTON / 1 mL in 1 SYRINGE, GLASS (0832-6085-89)
- 0832-6085 - Glatiramer Acetate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0832-6085-12 identifies a specific commercial package of 12 syringe, glass in 1 carton / 1 ml in 1 syringe, glass (0832-6085-89) of Glatiramer Acetate, a human prescription drug labeled by Upsher-smith Laboratories, Llc. This injection, solution is formulated for subcutaneous use and contains glatiramer acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on January 23, 2026. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.
How is this Upsher-smith Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00832608512. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.